MicroRNAs as disease progression biomarkers and therapeutic targets in experimental autoimmune encephalomyelitis model of multiple sclerosis

Multiple sclerosis is an autoimmune neurodegenerative disease of the central nervous system characterized by pronounced inflammatory infiltrates entering the brain, spinal cord and optic nerve leading to demyelination. Focal demyelination is associated with relapsing-remitting multiple sclerosis, wh...

Full description

Bibliographic Details
Main Authors: Bridget Martinez, Philip V Peplow
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2020-01-01
Series:Neural Regeneration Research
Subjects:
Online Access:http://www.nrronline.org/article.asp?issn=1673-5374;year=2020;volume=15;issue=10;spage=1831;epage=1837;aulast=Martinez
_version_ 1818254918752927744
author Bridget Martinez
Philip V Peplow
author_facet Bridget Martinez
Philip V Peplow
author_sort Bridget Martinez
collection DOAJ
description Multiple sclerosis is an autoimmune neurodegenerative disease of the central nervous system characterized by pronounced inflammatory infiltrates entering the brain, spinal cord and optic nerve leading to demyelination. Focal demyelination is associated with relapsing-remitting multiple sclerosis, while progressive forms of the disease show axonal degeneration and neuronal loss. The tests currently used in the clinical diagnosis and management of multiple sclerosis have limitations due to specificity and sensitivity. MicroRNAs (miRNAs) are dysregulated in many diseases and disorders including demyelinating and neuroinflammatory diseases. A review of recent studies with the experimental autoimmune encephalomyelitis animal model (mostly female mice 6–12 weeks of age) has confirmed miRNAs as biomarkers of experimental autoimmune encephalomyelitis disease and importantly at the pre-onset (asymptomatic) stage when assessed in blood plasma and urine exosomes, and spinal cord tissue. The expression of certain miRNAs was also dysregulated at the onset and peak of disease in blood plasma and urine exosomes, brain and spinal cord tissue, and at the post-peak (chronic) stage of experimental autoimmune encephalomyelitis disease in spinal cord tissue. Therapies using miRNA mimics or inhibitors were found to delay the induction and alleviate the severity of experimental autoimmune encephalomyelitis disease. Interestingly, experimental autoimmune encephalomyelitis disease severity was reduced by overexpression of miR-146a, miR-23b, miR-497, miR-26a, and miR-20b, or by suppression of miR-182, miR-181c, miR-223, miR-155, and miR-873. Further studies are warranted on determining more fully miRNA profiles in blood plasma and urine exosomes of experimental autoimmune encephalomyelitis animals since they could serve as biomarkers of asymptomatic multiple sclerosis and disease course. Additionally, studies should be performed with male mice of a similar age, and with aged male and female mice.
first_indexed 2024-12-12T17:03:36Z
format Article
id doaj.art-3e08435d28994605b8c2d6bfa9211d1f
institution Directory Open Access Journal
issn 1673-5374
language English
last_indexed 2024-12-12T17:03:36Z
publishDate 2020-01-01
publisher Wolters Kluwer Medknow Publications
record_format Article
series Neural Regeneration Research
spelling doaj.art-3e08435d28994605b8c2d6bfa9211d1f2022-12-22T00:18:03ZengWolters Kluwer Medknow PublicationsNeural Regeneration Research1673-53742020-01-0115101831183710.4103/1673-5374.280307MicroRNAs as disease progression biomarkers and therapeutic targets in experimental autoimmune encephalomyelitis model of multiple sclerosisBridget MartinezPhilip V PeplowMultiple sclerosis is an autoimmune neurodegenerative disease of the central nervous system characterized by pronounced inflammatory infiltrates entering the brain, spinal cord and optic nerve leading to demyelination. Focal demyelination is associated with relapsing-remitting multiple sclerosis, while progressive forms of the disease show axonal degeneration and neuronal loss. The tests currently used in the clinical diagnosis and management of multiple sclerosis have limitations due to specificity and sensitivity. MicroRNAs (miRNAs) are dysregulated in many diseases and disorders including demyelinating and neuroinflammatory diseases. A review of recent studies with the experimental autoimmune encephalomyelitis animal model (mostly female mice 6–12 weeks of age) has confirmed miRNAs as biomarkers of experimental autoimmune encephalomyelitis disease and importantly at the pre-onset (asymptomatic) stage when assessed in blood plasma and urine exosomes, and spinal cord tissue. The expression of certain miRNAs was also dysregulated at the onset and peak of disease in blood plasma and urine exosomes, brain and spinal cord tissue, and at the post-peak (chronic) stage of experimental autoimmune encephalomyelitis disease in spinal cord tissue. Therapies using miRNA mimics or inhibitors were found to delay the induction and alleviate the severity of experimental autoimmune encephalomyelitis disease. Interestingly, experimental autoimmune encephalomyelitis disease severity was reduced by overexpression of miR-146a, miR-23b, miR-497, miR-26a, and miR-20b, or by suppression of miR-182, miR-181c, miR-223, miR-155, and miR-873. Further studies are warranted on determining more fully miRNA profiles in blood plasma and urine exosomes of experimental autoimmune encephalomyelitis animals since they could serve as biomarkers of asymptomatic multiple sclerosis and disease course. Additionally, studies should be performed with male mice of a similar age, and with aged male and female mice.http://www.nrronline.org/article.asp?issn=1673-5374;year=2020;volume=15;issue=10;spage=1831;epage=1837;aulast=Martinezanimal model; blood plasma; blood serum; brain tissue; disease biomarkers; experimental autoimmune encephalomyelitis; micrornas; multiple sclerosis; spinal cord; therapeutic targets; urine exosomes
spellingShingle Bridget Martinez
Philip V Peplow
MicroRNAs as disease progression biomarkers and therapeutic targets in experimental autoimmune encephalomyelitis model of multiple sclerosis
Neural Regeneration Research
animal model; blood plasma; blood serum; brain tissue; disease biomarkers; experimental autoimmune encephalomyelitis; micrornas; multiple sclerosis; spinal cord; therapeutic targets; urine exosomes
title MicroRNAs as disease progression biomarkers and therapeutic targets in experimental autoimmune encephalomyelitis model of multiple sclerosis
title_full MicroRNAs as disease progression biomarkers and therapeutic targets in experimental autoimmune encephalomyelitis model of multiple sclerosis
title_fullStr MicroRNAs as disease progression biomarkers and therapeutic targets in experimental autoimmune encephalomyelitis model of multiple sclerosis
title_full_unstemmed MicroRNAs as disease progression biomarkers and therapeutic targets in experimental autoimmune encephalomyelitis model of multiple sclerosis
title_short MicroRNAs as disease progression biomarkers and therapeutic targets in experimental autoimmune encephalomyelitis model of multiple sclerosis
title_sort micrornas as disease progression biomarkers and therapeutic targets in experimental autoimmune encephalomyelitis model of multiple sclerosis
topic animal model; blood plasma; blood serum; brain tissue; disease biomarkers; experimental autoimmune encephalomyelitis; micrornas; multiple sclerosis; spinal cord; therapeutic targets; urine exosomes
url http://www.nrronline.org/article.asp?issn=1673-5374;year=2020;volume=15;issue=10;spage=1831;epage=1837;aulast=Martinez
work_keys_str_mv AT bridgetmartinez micrornasasdiseaseprogressionbiomarkersandtherapeutictargetsinexperimentalautoimmuneencephalomyelitismodelofmultiplesclerosis
AT philipvpeplow micrornasasdiseaseprogressionbiomarkersandtherapeutictargetsinexperimentalautoimmuneencephalomyelitismodelofmultiplesclerosis